Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses

Web

Nov. 4, 2019

SCIENTIFIC

BRAF fusions occur at low prevalence across many solid tumour types. Preclinical work confirms resistance to available BRAF inhibitors, fusion-specific sensitivity to MEK inhibition and promising activity of a next-generation RAF inhibitor.

https://www.cell.com/cell-reports/fulltext/S2211-1247(19)31186-6